By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



111 Speen Street, Suite 306

Framingham  Massachusetts   01701  U.S.A.
Phone: 508-861-7709 Fax: n/a


Key Statistics

Ownership: Private

Web Site: Alzheon


Company News
Alzheon To Present New Clinical Data And Analyses For ALZ-801 And Its Active Molecule Tramiprosate At The 13th International Conference On Alzheimer’s And Parkinson’s Diseases 2/13/2017 12:00:03 PM
Alzheon Appoints Neil Flanzraich, JD, As Chief Business Officer 2/13/2017 7:09:39 AM
Alzheon Appoints Nobel Laureate Stanley B. Prusiner, MD, As Chair Of Scientific Advisory Board 1/4/2017 10:03:26 AM
Alzheon Presents Analyses From Phase III Clinical Studies Showing Largest Clinical Effects Of Tramiprosate, The Active Molecule Of ALZ-801, In APOE4/4 Homozygous Patients With Mild Alzheimer’s Disease 12/9/2016 6:54:13 AM
Alzheon Publishes New Analyses From Phase III Studies Showing Clinical Benefit Of Tramiprosate In Alzheimer’s Patients Who Are Carriers Of APOE4, The Major Genetic Risk Factor In Up To 65 Percent Of Alzheimer’s Patients 10/24/2016 10:56:07 AM
Alzheon To Present At Upcoming Asian Healthcare And Scientific Conferences 10/4/2016 11:31:00 AM
Alzheon To Present At Upcoming Investor Conferences 9/21/2016 11:18:11 AM
Alzheon To Present At Upcoming Industry Conferences 9/7/2016 1:38:18 PM
Alzheon Presents Positive Results Of ALZ-801 Clinical Studies That Lead To Advancement To Pivotal Phase III Study In Alzheimer's Patients With APOE4/4 Homozygous Genotype 7/25/2016 10:47:33 AM
Alzheon To Present At The 2016 JMP Securities Life Sciences Conference 6/16/2016 10:19:10 AM